|
|
|
|
Institut National de la Santé et de la Recherche
Médicale U388, Institut Louis Bugnard, Centre Hospitalier
Universitaire Rangueil, 31403 Toulouse Cedex 04, France
Previous studies have shown that a subpopulation of the
catecholamine-degrading enzymes monoamine oxidase (MAO) A and B holds a
previously unknown regulatory site, the I2-imidazoline
binding site (I2BS). In the present work, we characterized
the isoforms of monoamine oxidases expressed in the rabbit renal
proximal tubule, defined their relationship with I2BS, and
investigated the ability of I2BS ligands to inhibit enzyme
activity in intact cells. Two findings indicate that MAO-B is the
predominant isoform expressed in the renal proximal tubule cells: 1)
Western blot performed with an anti-MAO-A/MAO-B polyclonal antiserum
revealed a single 55-kDa band corresponding to MAO-B; 2) enzyme assays
showed an elevated MAO-B activity
([14C]
-phenylethylamine oxidation:
Vmax = 1.31 ± 0.41 nmol/min/mg protein), whereas MAO-A activity was only detectable
([14C]5-HT oxidation: Vmax = 80.3 ± 19 pmol/min/mg protein). Photoaffinity labeling with the
I2BS ligand
[125I]2-(3-azido-4-iodophenoxy)-methylimidazoline
revealed a single 55-kDa band, which indicates that MAO-B of the renal
proximal tubule cells holds the I2 imidazoline binding
site. [3H]Idazoxan binding studies and enzyme assays
showed that, in intact cells, I2BS ligands bind to and
inhibit MAO-B. Indeed, the increase in the accessibility of
intracellular compartment by cell permeabilization did not enhance
[3H]idazoxan binding, which indicates that, in intact
cells, intracellular I2BS are fully occupied by imidazoline
ligands. In addition, enzyme assays showed that incubation of proximal
tubule cells with imidazoline ligands leads to a complete,
dose-dependent inhibition of MAO activity. These data show the
predominant expression of MAO-B in rabbit renal proximal tubule and its
regulation by imidazoline ligands in intact cells.
This article has been cited by other articles:
![]() |
J. W. Lohr, G. R. Willsky, and M. A. Acara Renal Drug Metabolism Pharmacol. Rev., March 1, 1998; 50(1): 107 - 142. [Abstract] [Full Text] [PDF] |
||||